NCT02432378 2025-06-19
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
Phase 1/2 Terminated
Clinical Trials
9 trialsNCT00538031 2023-04-21
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT03896113 2020-01-10
CELEBRIDO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT00152828 2016-02-09
Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix
University Health Network, Toronto
Phase 1/2 Completed
NCT01175772 2015-06-23
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
HaEmek Medical Center, Israel
Phase 2 Terminated
NCT00084370 2013-08-22
Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy
University of Alabama at Birmingham
Phase NA Withdrawn
NCT00231829 2012-04-24
A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers
Montefiore Medical Center
Phase 2 Terminated
NCT01124435 2010-06-04
carbo-cox2
Catholic University of the Sacred Heart
Phase 2 Completed